CDK4 and glioblastoma: More recently, Qi et al. showed that overexpression of PIKE-A (Phosphoinositide 3-kinase enhancer) and Cdk4 in p53-Pten double KO glioblastoma mouse model synergistically shortens the latency of tumor onset and survival compared to control mice (Qi et al., 2017).